A safety communication discouraging use of power morcellation during hysterectomy or myomectomy for fibroids has been issued by the Food and Drug Administration (FDA) because of concern about risk of inadvertent spread of unsuspected cancer to abdominal and pelvic cavities.
A safety communication discouraging use of power morcellation during hysterectomy or myomectomy for fibroids has been issued by the Food and Drug Administration (FDA) because of concern about risk of inadvertent spread of unsuspected cancer to abdominal and pelvic cavities. The FDA’s recommendations to health care providers include not using the technology in women with suspected or known uterine cancer. Recommendations to women undergoing laparoscopic hysterectomy or myomectomy include asking your health care provider if power morcellation will be performed and if so, why it is considered the best treatment option for you.
Perspective from Deputy Editor Jon I. Einarsson, MD, PhD, MPH
“The FDA safety communication discourages use of laparoscopic power morcellation and indicates that the practice will be further evaluated by the Obstetrics and Gynecological Medical Devices Panel. Physicians are encouraged to consider all available treatment options and to discuss the risks and benefits of all options with their patients. Several institutions have already stopped or significantly restricted the use of open power morcellation due to concerns about the spread of undiagnosed malignancy.
In our experience, in-bag morcellation is a feasible approach to laparoscopic specimen retrieval which may significantly limit potential spread of occult malignancy during laparoscopy. In-bag morcellation is being actively investigated by several centers at the present time because more information is needed about the safety and efficacy of this approach. Alternative methods of tissue extraction that do not involve traditional morcellators are also being developed. I suspect that this field will continue to evolve very rapidly during the next few months.”
For more coverage from Contemporary OB/GYN on morcellation, read our March cover story.
Study reveals critical gaps in care for PCOS patients
May 17th 2024A new study presented at the 2024 ACOG Annual Clinical and Scientific Meeting highlighted significant gaps in polycystic ovary syndrome (PCOS) care, revealing widespread patient dissatisfaction and the urgent need for improved provider education and comprehensive treatment approaches.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Advancing obstetric and gynecologic surgery through robotic innovation
April 30th 2024Explore how robotic surgery revolutionizes obstetric and gynecologic procedures, offering enhanced precision, reduced complications, and improved patient outcomes, while also examining challenges and future prospects in the field.
Read More